射频消融联合经动脉化学栓塞和抗病毒治疗对原发性慢性HBV

StephenW

J BUON. 2019 Sep-Oct;24(5):1979-1984.
Effects of radiofrequency ablation combined with transarterial chemoembolization and antiviral therapy on the prognosis and quality of life in primary chronic HBV-related liver cancer.
Lu B1, Zhu L, Wang X, Zhong L, Cheng Y, Fan J, Yu L.
Author information

1
    Department of Infectious Disease, the fourth Hospital of Harbin Medical University, Harbin 150001, China.

Abstract
PURPOSE:

To investigate the effects of radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) and antiviral therapy on the prognosis and quality of life in primary chronic hepatitis B virus (HBV)-related liver cancer.
METHODS:

A total of 80 hepatitis B patients complicated with hepatocellular carcinoma treated in our hospital from March 2016 to February 2018 were selected and divided into the control group (n=40) and the observation group (n=40) using a random number table. The patients in the control group were treated with RFA combined with TACE, while those in the observation group were additionally treated with entecavir. The HBV-DNA load and alpha fetoprotein (AFP) level during intervention and the liver function before and after intervention were compared between the two groups. The patients were followed up for 2 years after treatment, the clinical therapeutic effects in both groups were recorded, and the correlations of HBV-DNA load, AFP level and alanine aminotransferase (ALT) level with the survival time of patients were analyzed.
RESULTS:

At 1 and 3 months after intervention, the HBV-DNA load in the observation group was significantly lower than that before intervention (p<0.05), and it was also significantly lower than in the control group (p<0.05). At 1 and 3 months after intervention, the AFP level was lowered in both groups compared with that before the intervention (p<0.05), and it was also lower in the observation group than in the control group (p<0.05). After intervention, the levels of total bilirubin (Tbil), aspartate aminotransferase (AST) and ALT in the observation group were lower than those before the intervention (p<0.05), and they were also lower than those in the control group (p<0.05). Moreover, the disease progression in the observation group was significantly lower than in the control group, and the 1-year and 2-year survival in the observation group was longer compared with the control group. The HBV-DNA load, AFP level and ALT level were negatively correlated with the survival of patients (p<0.05).
CONCLUSIONS:

The RFA combined with TACE and regular antiviral therapy for HBV-related liver cancer is of significance in reducing the HBV-DNA load and tumor markers, improving the liver function, promoting the overall clinical therapeutic effect and prolonging the survival of patients.

PMID:
    31786864

StephenW

J BUON。 2019年9月-10月; 24（5）：1979-1984。
射频消融联合经动脉化学栓塞和抗病毒治疗对原发性慢性HBV相关肝癌的预后和生活质量的影响。
陆B1，朱L，王X，钟L，程Y，范J，于L.
作者信息

1个
    哈尔滨医科大学附属第四医院感染科，哈尔滨150001。

抽象
目的：

目的探讨射频消融（RFA）联合经动脉化学栓塞（TACE）和抗病毒治疗对原发性慢性乙型肝炎病毒（HBV）相关肝癌的预后和生活质量的影响。
方法：

2016年3月至2018年2月在我院收治的80例乙型肝炎合并肝细胞癌患者，采用随机数字表分为对照组（n = 40）和观察组（n = 40）。对照组患者接受RFA联合TACE治疗，观察组患者接受恩替卡韦治疗。比较两组干预期间的HBV-DNA负荷和甲胎蛋白（AFP）水平以及干预前后的肝功能。治疗后随访2年，记录两组临床疗效，分析HBV-DNA负荷，AFP水平和丙氨酸转氨酶（ALT）水平与患者生存时间的关系。
结果：

干预后1个月和3个月，观察组的HBV-DNA负荷显着低于干预前（p <0.05），也显着低于对照组（p <0.05）。干预后1和3个月，两组的AFP水平均较干预前降低（p <0.05），观察组的AFP水平也低于对照组（p <0.05）。干预后，观察组的总胆红素（Tbil），天冬氨酸转氨酶（AST）和ALT水平低于干预前（p <0.05），也低于对照组（p <0.05）。 0.05）。此外，观察组的疾病进展显着低于对照组，观察组的1年和2年生存期比对照组更长。 HBV-DNA负荷，AFP水平和ALT水平与患者的生存呈负相关（p <0.05）。
结论：

RFA与TACE联合常规抗病毒治疗对HBV相关性肝癌具有重要意义，它可以降低HBV-DNA负荷和肿瘤标志物，改善肝功能，促进整体临床治疗效果并延长患者生存期。

PMID：
    31786864